inc alexion biopharmaceut compani engag discoveri develop deliveri biolog
therapeut product treatment diseas includ hematolog neurolog diseas cancer autoimmun disord
compani one market product soliri eculizumab therapi approv treatment patient paroxysm
nocturn hemoglobinuria pnh june european commiss approv use soliri patient pnh
european union also serv basi approv iceland norway alexion focus product develop
program anti-inflammatori therapeut diseas
rank
return equiti
incom statement summari figur million
long-term fundament rank
short-term technic rank
rank number list
medical/biomed compani trade today unit
state market capit billion
medical/biomed compani highest total
asset highest revenu
within sector rel low price-to-earnings moder p/
moder rel roe roa
short term fall combin weak volum result
weak momentum fall day
significantli price discount
move averag price rang
trade discount
high premium
low invest exactli one year ago worth
capit gain
stock score set
involv valuat size
financi perform
rank accord
averag valu
rank lowest
rank
stock score set
price perform trade
volum rank
accord averag
valu paramet
highest rank
lowest rank
inc place bss rank perform past year percentil rank
inc largest revenu ft global
rank newsweek corpor knight capit world greenest compani outstand score
carbon product
largest revenu forb global
medical/biomed sector total bracket
revenu billion aggreg sector revenu
billion previou year
net profit million aggreg sector net profit
billion previou year
mcap billion aggreg sector mcap
billion previou year
price discount volum
weight averag price may appeal
market stock unit trade
today stock rel strength
mean outperform market
price map ratio
price lower bolling band
stock also oversold accord indic
 ratio defin jame tobin mcap divid
total asset compar rest market
stock under-valued
satisfi two criteria benjamin graham
current ratio two current asset time
stabil growth earn last year defin
two declin greater year-end
earn declin earn last
satisfi criteria joseph piotroski pass
qualiti earn oper cash-flow exce net
reduct total share issu
improv gross margin
improv asset turnov growth revenu
exceed growth asset
debt equiti ratio well within safe benchmark
figur moreov improv past three year
turnov quarter
fall rise last three month number fall
outnumb rise
indic exponenti move averag ema
minu ema neg
suggest bearish signal ema well
ema fall anoth bearish signal
past day ratio time
suggest downsid map decreas
decreas anoth bearish indic
 stock trade five-month low today
price-to-earnings versu sector averag
market averag
price/sal versu sector averag market
averag estim share trade
current year price/sal forward year price/sal
averag annual compound return share price
last year under-perform averag
annual compound return
return equiti versu sector averag
market averag
total liabilities/ ebitda equal
compar unfavour joseph piotroski benchmark
return asset versu sector averag
market averag
return capit employ versu sector averag
market averag
net profit margin averag last year
lower sector averag suggest low
margin safeti
per du pont analysi return equiti less
stellar comput net profit margin
time asset turnov sales/asset time leverag factor
total assets/sharehold equiti
deterior last year
trail twelv month price-to-earnings cyclic
adjust price earn cape cape
mid-rang stock histor
cape develop economist robert shiller base
methodolog benjamin graham david dodd
smooth earn across period base move
averag quarter
earn yield less benchmark yield
earn yield bond yield
price sale
return asset
return equiti
volum index average
stock trade low high
averag daili volatil place
stock quartil market mean mildli volatil
result report
us million except per share data share outstand
sale
research develop
sell gener administr
amort purchas intang asset
chang fair valu conting consider
incom expens
incom expens
incom incom tax
share use comput earn per common share
cash equival
prepaid expens current asset
properti plant equip net
right use oper asset
liabil stockhold equiti
account payabl accru expens
current portion long-term debt
current portion conting consider
commit conting
share issu march decemb
treasuri stock cost share march
decemb respect
accumul comprehens loss
total liabil stockhold equiti
flow oper activ
adjust reconcil net incom net cash flow
depreci amort
chang fair valu conting consider
unreal loss gain forward contract
unreal gain equiti invest
chang oper asset liabil
prepaid expens right use oper asset asset
account payabl accru expens leas liabil
net cash provid oper activ
flow invest activ
purchas available-for-sal debt secur
proce matur sale available-for-sal debt
purchas mutual fund relat nonqualifi defer
proce sale mutual fund relat nonqualifi
purchas properti plant equip
purchas strateg invest
purchas intang asset
net cash provid use invest activ
flow financ activ
payment term loan
payment revolv credit facil
repurchas common stock
net proce issuanc common stock share-bas
net cash use financ activ
effect exchang rate chang cash cash equival
restrict cash
net chang cash cash equival restrict cash
cash equival restrict cash begin
cash equival restrict cash end period
quarterli report sequenti growth
quarterli report alexion pharmaceut report sequenti rise quarterli revenu
announc total revenu quarter-end march
previou quarter year-earli period
sequenti growth revenu
compar previou correspond period pcp year-over-year ep revenu
net profit
pcp growth ep
pcp growth revenu
pcp growth net profit
result report annual
us million except per share data share outstand
sale
research develop
sell gener administr
acquir in-process research develop
amort purchas intang asset
chang fair valu conting consider
impair intang asset
incom expens
incom expens
incom incom tax
share use comput earn per common share
cash equival
prepaid expens current asset
properti plant equip net
liabil stockhold equiti
account payabl accru expens
current portion long-term debt
current portion conting consider
commit conting
share issu respect
treasuri stock cost share
accumul comprehens loss
total liabil stockhold equiti
flow oper activ
adjust reconcil net incom net cash flow
depreci amort
impair asset
chang fair valu conting consider
payment conting consider
non-cash expens acquir ipr
unreal gain loss forward contract
unreal gain equiti invest
chang oper asset liabil exclud effect
prepaid expens asset
account payabl accru expens liabil
net cash provid oper activ
flow invest activ
purchas available-for-sal debt secur
proce matur sale available-for-sal debt
purchas mutual fund relat nonqualifi defer
proce sale mutual fund relat nonqualifi
purchas properti plant equip
purchas invest
net cash provid use invest activ
flow financ activ
proce revolv credit facil
payment term loan
repurchas common stock
net proce issuanc stock share-bas
payment conting consider
repay development-rel grant
net cash use financ activ
effect exchang rate chang cash cash equival
restrict cash
net chang cash cash equival restrict cash
cash equival restrict cash begin
cash equival restrict cash end period
earn cont op margin
annual report alexion pharmaceut profit hit fall
report net profit year-end decemb
previou year
major chang compar previou year
total revenu
sale market expens sale
good sold sale
work capit total asset
retain earn total asset
total current asset total asset
fix asset total asset
ebit margin
ebit total asset
profit tax sale
current ratio
total non-curr asset total asset
total revenu total asset steadi
amortis sale
tax expens sale
debt equiti steadi
total liabil total asset steadi
intang total asset
current inventori total asset steadi
amortis steadi us us
profit/ loss tax
year-on-year comparison per share figur
year-on-year comparison perform ratio
return equiti
return asset
total debt net tangibl asset
total liabil ebitda
debt/equ
total liabilities/tot asset
common size ratio asset
total non-curr asset total asset
intang total asset
total current asset total asset
fix asset total asset
current inventori total asset
common size ratio sale
sale market expens sale
good sold sale
amortis sale
profit tax sale
tax expens sale
five-year record growth perform
last year total revenu averag ebitda averag net profit averag
compound annual growth rate compound-annual-growth-rate averag total revenu net profit ebitda
five-year record ebitda oper profit net profit roe roa roce
net profit margin average figur
return equiti
return asset
return capit employ
profit tax
oper cash flow
sale
base issu equiti share market
capitalis billion largest
medical/biomed compani total revenu
announc annual gener
meet take place tuesday may
today announc financi result first quarter
total revenu first quarter million
percent increas compar period
neg impact foreign currenc total revenu year-over-
year percent million inclus hedg
detail click
april alexion report first quarter result
announc compani report financi result
first quarter end march us financi
market open april follow releas
financi result alexion manag conduct confer
call audio webcast
detail click
may wedbush secur senior vice presid equiti
research laura chico ph initi coverag
stock healthcar biotech space
alnx dova
lo angel may -- wedbush secur pleas
announc senior vice presid equiti research
laura chico ph initi coverag six stock
healthcar space initi follow
detail click
may alexion present ub global healthcar
announc manag present ub global
healthcar confer new york ny monday may
et
audio webcast present avail live
access webcast http //ir alexion com
detail click
may alexion present capit market
announc manag present capit
market annual healthcar confer new york ny
tuesday may et
audio webcast present avail live
access webcast http //ir alexion com
detail click
april alexion receiv posit chmp opinion
ultomiri ravulizumab adult paroxysm
 final european commiss decis anticip june
 ultomiri potenti becom new standard
care complement inhibitor-na patient patient
switch soliri eculizumab
today announc european medicin
agenc ema committe medicin product
use chmp adopt posit opinion recommend
market author ultomiri ravulizumab first
long-act complement inhibitor administ everi
detail click
report buy sell trail month continu
share
share
report institut buy sell share
hold end quarter
report hold institut march
total report hold institut share
report hold institut
issu capit
net buying/ sell institut trail month ttm
usd valu
new york mellon corp
montreal
america corp de
state treasur state michigan
new patent issu us pto
view detail click patent link
treatment paroxysm nocturn hemoglobinuria hemolyt anemia diseas state involv
intravascular extravascular hemolysi
method treat atyp hemolyt urem syndrom antibodi
method treat lysosom acid lipas defici patient
composit compris antibodi
reagent method detect pnh type ii white blood cell identif risk factor
thrombot disord
bone deliveri conjug method use target protein bone
method composit kit treatment matrix miner disord
method produc antibodi
kit compris formul antibodi
method shift isoelectr profil protein product use thereof
inc alexion biopharmaceut compani engag discoveri develop
deliveri biolog therapeut product treatment diseas includ hematolog neurolog diseas
cancer autoimmun disord compani one market product soliri eculizumab therapi
approv treatment patient paroxysm nocturn hemoglobinuria pnh june european
commiss approv use soliri patient pnh european union also serv
basi approv iceland norway alexion focus product develop program anti-
inflammatori therapeut diseas
board manag creation sharehold valu
board director year sinc appoint
chief patient
head research
chief strategi
year experi biopharmaceut
extens experi execut lead global innov
deep develop regulatori commerci experi
chief execut offic alexion
dr hantson becam chief execut offic alexion march
prior join alexion dr hantson presid
chief execut offic baxalta incorpor led baxalta
success spin-off public compani baxter intern
inc juli presid baxter bioscienc
join baxter may establish bioscienc
divis innov specialti rare diseas compani
pipelin new product candid product
launch prior baxter dr hantson held
sever leadership role novarti ag includ ceo
pharma north america ceo europ presid
pharma canada prior novarti dr hantson spent year
johnson johnson role increas respons
market research develop dr hantson receiv
ph motor rehabilit physic therapi master
degre physic educ certif high
secondari educ univers louvain
mr brennan serv interim chief execut offic alexion
decemb march
chief execut offic execut director
astrazeneca plc one world largest pharmaceut
compani mr brennan work astrazeneca increas
role respons includ
execut vice presid north america
senior vice presid commerci portfolio
manag prior merger astra ab
zeneca plc serv senior vice presid busi
plan develop astra pharmaceut lp
american subsidiari astra ab mr brennan began career
merck co inc rose sale repres
 divis gener manag chibret intern
french subsidiari merck receiv ba busi
administr gettysburg colleg
chairman board truste
mr coughlin serv advisor chairman ceo
ltd global provid diversifi product
servic industri execut
vice presid chief offic tyco
period signific intern growth
restructur mr coughlin previous serv interpubl
group compani inc execut vice presid chief
oper offic
serv execut vice presid chief offic
pharmacia corpor presid
nabisco group hold
execut vice presid chief offic
nabisco mr coughlin held variou posit
sterl winthrop incorpor includ chief
offic mr coughlin receiv bs account boston
alexion director sinc committe membership audit
financ leadership compens chair public
signific experi execut compens polici
year chief human resourc senior execut
function larg public complex global organ includ
bring valu oper perspect board matter
talent recruit develop execut compens
benefit leadership
extens global deep experi
mr mollen serv execut vice presid
resourc emc corpor may
retir februari includ two year special
advisor presid join emc senior vice
presid human resourc septemb prior join
emc mr mollen senior vice presid human resourc
citigroup inc financi servic compani juli
septemb prior held number
posit increas respons harri corp
intern commun technolog compani includ
vice presid administr mr mollen serv director
number not-for-profit profession board includ
new england healthcar institut hr polici associ
center execut compens advisori
board member work mother magazin
chairman board truste worcest polytechn
institut mr mollen receiv econom st john
fisher colleg master degre labor relat st
franci colleg pennsylvania
alexion director sinc committe membership audit
financ scienc innov public compani
nomin corpor govern scienc innov
broad experi serv director investor
biotechnolog compani provid strateg perspect
extens experi evalu develop strateg
busi plan biotechnolog industri
deep transact experi biotechnolog industri
provid tremend valu evalu extern opportun
signific industri product develop knowledg
year career invest biotechnolog compani
dr baker co-manag member baker bro advisor lp
invest advis focus invest life scienc
biotechnolog compani dr baker brother julian
baker start fund manag career
co-found biotechnolog invest partnership tisch
famili dr baker hold ph immunolog
stanford univers also complet two year
dr rummelt serv chief execut offic
interpharmalink ag manag consult firm focus
advis compani healthcar industri sinc januari
decemb januari dr rummelt
group head qualiti assur technic oper
novarti member execut committe
novarti januari resign januari
join sandoz pharma ltd held variou
posit increas respons pharma develop
appoint head world-wide technic research
develop posit retain follow merger
creat novarti dr rummelt
serv head technic oper novarti
pharmaceut divis global ceo
sandoz dr rummelt graduat ph
pharmaceut scienc univers erlangen-
extens experi biopharmaceut industri
broad experi organ focus develop
experienc biopharmaceut chief execut offic strong
background across commerci function
deep experi invest biotechnolog compani provid
valuabl insight evalu extern opportun
dr nader serv presid chief execut offic
execut director np pharma global biotechnolog
compani focus deliv innov therapi
patient rare diseas prior np dr
nader ventur partner capit ventur capit
firm previous serv north america leadership
aventi pharma predecessor compani hold
number execut posit integr healthcar market
medic regulatori affair also led global commerci
oper pasteur vaccin divis rhone-poulenc
dr nader earn french doctor medicin st
joseph univers lebanon physician execut
univers tennesse
alexion director sinc committe membership audit
financ nomin corpor govern chair
bring strong corpor govern legal expertis
broad experi global complianc strateg plan data
privaci regulatori matter
extens experi lead legal function larg public
compani global oper regul industri
extens global deep experi
ms reinsdorf previous serv execut vice presid
gener counsel global
leader build product technolog integr solut
energi storag follow merger septemb
serv execut vice presid
gener counsel march septemb
prior johnson control ms reinsdorf serv vice
presid gener counsel secretari bard inc
vice presid corpor secretari tyco vice
presid associ gener counsel pharmacia
corpor assist gener counsel chief legal
counsel corpor monsanto compani ms reinsdorf
earn bachelor degre univers rochest
 cornel law school
nomin corpor govern scienc innov
year experi biopharmaceut
deep experi research earli late stage
extens experi build lead organ
expand compani pipelin asset overse
commerci develop innov therapeut product
across rang area
bring valuabl perspect board chief execut
offic biopharmaceut industri
sinc juli dr friedman serv chairman
board director chief execut offic madrig
pharmaceut dr friedman serv ceo director
incyt corpor novemb retir
januari serv presid research
develop dupont-merck compani
also presid research
laboratori wholly-own subsidiari dupont compani
also held execut posit dupont
laboratori merck sharp dohm corpor prior
tenur merck dupont dr friedman associ
professor medicin pharmacolog harvard medic
school dr friedman diplomat american board
intern medicin member american societi
clinic investig dr friedman receiv biolog
princeton univers harvard medic
sinc septemb dr dunsir serv presid
chief execut offic lundbeck a/
dr dunsir serv presid chief execut
offic millennium pharmaceut inc led
transform compani biotechnolog industri
leader prior millennium becam takeda oncolog dr
dunsir led novarti north america oncolog busi
period signific growth tenur
also previous serv presid chief execut
offic varieti research
develop commerci posit sandoz ag
januari march dr dunsir serv
presid chief execut offic
novel therapeut dr dunsir receiv medic degre
univers witwatersrand johannesburg south africa
price close today/pric close period ago rank
percentil within entir market
price period/numb period
report report prepar minkabu infonoid inc minkabu analyst opinion project report
suppli global market intellig llc compani profil company-rel inform co-own
minkabu infonoid inc pk clean ltd buysellsign group compani stock index price suppli
stock exchang tradeg exchang euronext deutsch brse ag bme stuttgart stock exchang tradeg exchang
exchang clear limit taiwan stock exchang tokyo stock exchang nagoya stock exchang toronto stock exchang
express opinion analyst sole person opinion author contributor report minkabu
respons accuraci complet reliabl timeli inform opinion respons error
omiss therein assum liabil direct indirect loss damag particular lost profit may
incur result relianc inform use report inform report may contain project
opinion assumpt estim forecast relat futur busi perform event intend exampl
repres predict minkabu current futur perform compani secur
minkabu make warranti regard accuraci reliabl project opinion assumpt estim forecast
liabil damag kind aris relianc inform forward-look statement guarante
futur perform involv risk uncertainti actual result may differ forward-look statement result
variou factor minkabu oblig updat correct inform report constitut recommend
make invest purchas sell specif invest product report intend give financi
invest advic conduct care independ analysi seek advic profession advisor
suitabl invest need minkabu express opinion compani secur invest
product fluctuat futur perform thereof stock price rate comment includ target price buy
sell hold creat aggreg opinion individu investor opinion analyst secur
compani rate overvalu under-valued fairlyvalu fair stock price other display ancillari
rate object fact base statist record minkabu express opinion compani secur
invest product fluctuat futur perform thereof therebi either
minkabu repres warrant report appropri avail view download locat
exclus respons complianc applic local law regul view download report report
intend use inform refer purpos constitut solicit offer make
invest purchas sell specif invest product
minkabu regist broker dealer invest advisor analyst invest banker underwrit minkabu may hold
secur refer report includ deriv instrument may busi relat compani discuss
herein without prior written consent minkabu reproduct copi transmiss transfer distribut public
similar action content report shall made
